(Not for submission under 37 CFR 1.99) (Use several sheets if necessary)

Comparable to PTO/SB/08a (05-07)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

				U.	S. PATENTS	
Examiner Initial*	Cite No.	Patent Number	Kind Code	Issue Date yyyy/mm/dd	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments
	1.	2928833		1960-03-15	Leake et al	
	2.	4005208		1977-01-25	Bender	
	3.	4599338		1986-07-08	Regnier et al.	This patent appears to be an English language equivalent toEP0149578 cited herein.
	4.	5041448		1991-08-20	Janssens	
	5.	5051517		1991-09-24	Findeisen	This patent appears to be an English language equivalent toEP0399285 cited herein.
	6.	5223499	Α	1993-06-29	Greenlee	
	7.	5234897	Α	1993-08-10	Findeisen et al.	
	8.	5258380	Α	1993-11-02	Janssens	
	9.	5266555	A	1993-11-30	Findeisen et al.	This patent appears to be an English language equivalent toEP0524482 cited herein.
	10.	5389642	Α	1995-02-14	Dorsch	
	11.	5470579	A	1995-11-28	Bonte et al.	This patent appears to be an English language equivalent toWO9107945 cited herein.
	12.	5719279	A	1998-02-17	Kuefner-Muhl et al.	This patent appears to be an English language equivalent toWO94/03456 cited herein.
	13.	5753635	Α	1998-05-19	Buckman	
	14.	6303661	В1	2001-10-16	Demuth	
	15.	6342601	B1	2002-01-29	Bantick	
	16.	6548481	B1	2003-04-15	Demuth et al.	
	17.	6579868	B1	2003-06-17	Osamu Asano	
	18.	6821978	B2	2004-11-23	Chackalamannil	
	19.	6869947	B2	2005-03-22	Kanstrup	
	20.	7060722	B2	2006-06-13	Kitajima	
	21.	7074794	B2	2006-07-11	Kitajima	This patent appears to be an English language equivalent toWO2002/14271 cited herein.
	22.	7074798	B2	2006-07-11	Yoshikawa	
	23.	7074923	B2	2006-07-11	Dahanukar	
	24.	7109192	B2	2006-09-19	Hauel	
	25.	7179809	B2	2007-02-20	Eckhardt	
	26.	7183280	B2	2007-02-27	Himmelsbach	
	27.	7192952	B2	2007-03-20	Kanstrup	
	28.	7217711	B2	2007-05-15	Eckhardt	
	29.	7235538	B2	2007-06-26	Kanstrup et al.	

U.S. PATENT APPLICATION PUBLICATIONS

Examiner:	/Mark Berch/ (04/16/2008)	Date Considered:					
*L .	T '2' 1'C '2 2' '1 1 1 1 1	 	'A MPER C 4'	(00 D	1.	.1	1

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Not for submission under 37 CFR 1.99) (Use several sheets if necessary)

Comparable to PTO/SB/08a (05-07)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

Examiner Initial*	Cite No.	Publication Number	Kind Code	Publication Date yyyy/mm/dd	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments
	1.	11/744700		2007-05-04	Sieger	
	2.	11/744701		2007-05-04	Kohlrausch	
	3.	2002/0161001	A1	2002-10-31	Kanstrup	
	4.	2002/0169174	A1	2002-11-14	Chackalamannil et al.	
	5.					This document appears to be an apparent English language equivalent to
		2002/0198205	A1	2002-12-26	Himmelsbach	WO2002068420 cited herein.
	6.	2003/0199528	A1	2003-10-23	Kanstrup	
	7.	2003/0232987	A1	2003-12-18	Dahanukar et al.	
	8.	2003/0236272	A1	2003-12-25	Carr	
	9.	2003/0105077	A1	2003-06-05	Kanstrup, A.B. et al.	
	10.	2004/0034014	A1	2004-02-19	Kanstrup, A.B. et al.	
	11.	2004/0077645	A1	2004-04-22	Himmelsbach et al.	This document appears to be an apparent English language equivalent to WO2002068420 cited herein.
	12.	2004/0087587	A1	2004-05-06	 Himmelsbach	
	13.	2004/0116328	A1	2004-06-17	Yoshikawa et al.	This document appears to be an apparent English language equivalent to WO03104229 cited herein.
	14.	2004/0138215	A1	2004-07-15	Eckhardt	This document appears to be an apparent English language equivalent to WO2004/046148 cited herein.
	15.	2005/0020574	A1	2005-01-27	Hauel, N. et al.	
	16.	2005/0026921	A1	2005-02-03	Eckhardt	
	17.	2005/0130985	A1	2005-06-16	Himmelsbach	
	18.	2005/0171093	A1	2005-08-04	Eckhardt et al.	
	19.	2005/0187227	A1	2005-08-25	Himmelsbach et al.	
	20.	2005/0203095	A1	2005-09-15	Eckhardt	
	21.	2005/0234108	A1	2005-10-20	Himmelsbach et al.	
	22.	2005/0261352	A1	2005-11-24	Eckhardt	
	23.	2006/0004074	A1	2006-01-05	Eckhardt	
	24.	2006/0058323	A1	2006-03-16	Eckhardt et al.	
	25.	2006/0063787	A1	2006-03-23	Yoshikawa	
	26.	2006/0094722	A1	2006-05-04	Yasuda	This document appears to be an apparent English language equivalent to WO2004/028524 cited herein.
	27.	2006/0142310	A1	2006-06-20	Pfrengle et al.	This document appears to be an apparent English language equivalent to WO2006/048427 cited herein.
	28.	2006/0173056	A1	2006-08-03	-	77 O 2 3 0 0 7 0 7 2 7 0 10 0 11 GHI.
	29.	2006/0205711	A1	2006-09-14	Himmelsbach	This document appears to be an apparent English language equivalent to DE10117803 cited herein.
	30.	2006/0247226	A1		Himmelsbach	
	31.	2007/0027168	A1		Pfrengle et al.	
	32.	2007/0088038	A1	2007-04-19	Eckhardt	

Examiner: /Mark Berch/ (04/16/2008) Date Considered:

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Not for submission under 37 CFR 1.99) (Use several sheets if necessary)

Comparable to PTO/SB/08a (05-07)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

	U.S. PATENT APPLICATION PUBLICATIONS								
Examiner Initial*			Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments					
	33.	2007/0093659	A1	2007-04-26	Bonfanti				
	34.	2007/0142383	A1	2007-06-21	Eckhardt				
	35.	2007/0281940	A1	2007-12-06	Dugi				
	36.	2007/0219178	A1	2007-09-20	Muramoto				

	FOREIGN PATENT DOCUMENTS									
		Foreign				Name of Patentee	Pages, Columns, Lines where Relevant Passages or Relevant			
Examiner	Cite	Document	Country	Kind	Publication	or Applicant of	Figures Ameson on Dolovont	,		
Initial*	No.	Number	Code	Code	Date	cited Document	Comments	$\sqrt{1}$		
	1.	2136288	CA	A1	1995-05-24	Merck Patent GmbH	This document appears to be an apparent English language equivalent to EP0657454 cited herein			
	2.	2418656	CA	A1	2002-02-21	Mitsubishi Pharma Corporation				
	3.	2496249	CA	A1	2004-04-03	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004018468 cited herein			
	4.	2496325	CA	A1	2004-03-04	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO20040184687 cited herein			
	5.	2505389	CA	A1	2004-05-21	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004041820 cited herein			
	6.	2508233	CA	A1	2004-06-17	BI Pharma GmbH & Co. KG	This document appears to be an apparent English language equivalent to WO2004050658 cited herein			
	7.	2529729	CA	A1	2004-12-23	BI International GmbH	This document appears to be an apparent English language equivalent to WO2004111051 cited herein			
	8.	2543074	CA	A1	2005-06-30	BI International GmbH	This document appears to be an apparent English language equivalent to WO2005/058901 cited herein			
	9.	2555050	CA	A1	2005-09-15	BI International GmbH	This document appears to be an apparent English language equivalent to WO2005/085246 cited herein			
	10.	2556064	CA	A1	2005-09-09	BI International GmbH	This document appears to be an apparent English language equivalent to WO2005/082906 cited herein			
	11.	2590912	CA	A1	2006-06-29	Dainippon Sumitomo Pharma Co., Ltd.	This document appears to be an English language equivalent to WO2006068163 cited herein			
	12.	10109021	DE	A1	2002-09-05	Boehringer Ingelheim Pharma KG	US2006/0205711 cited herein appears to be an apparent English language equivalent			

 $^{^{1}}$ $\sqrt{}$ indicates English Language translation is attached

Examiner: /Mark Berch/ (04/16/2008) Date Considered:

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Not for submission under 37 CFR 1.99) (Use several sheets if necessary)

Comparable to PTO/SB/08a (05-07)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

				FOREIG	<u>N PATENT I</u>	OCUMENTS		
	1.2	40447000			0000 40 04	Boehringer Ingelheim		
	13.	10117803	DE	A1	2002-10-24	Pharma KG	LICATION 229 sited barain appears to be	
	14.	0149578	EP	A2	1985-07-24	ADIR	US4599338 cited herein appears to be an apparent English language equivalent	
							US5051517 cited herein appears to be	
	15.	0399285		A1	1990-11-28		an apparent English language equivalent	
	16.	0400974	EP	A2	1990-05-12	Merck & Co. Inc.		Ļ ,
	17.	0412358	EP	A1	1991-02-13	Bayer AG		1
	18.	0524482	EP	A1	1993-01-27	Baver AG	US5266555 cited herein appears to be an apparent English language equivalent	
	19.	0657454		A1		Merck Patent GmbH	CA2136288 cited herein appears to be an apparent English language equivalent	
	20.	1054012		A1	1	Eisai Co. Ltd	equivalent	
	21.	1338595		A2		Eisai Co. Ltd		
	22.	1514552		A1	+	Eisai Co. Ltd		
						Takeda Pharmaceutical		
	23.	1537880	EP	A1	2005-08-06	Company Limited		
	24.	385302	ES	A1	1973-04-16	Laboratorios Miquel		1
	25.	2707641	FR	A1	1995-01-20	Fournier Ind. Et Sante		
	26.	2003/300977	JP		2003-10-21			1
	27.	2006/045156	JP		2006-02-16	Sumitomo Pharma		1
	28.	S37-4895	JP		1962-06-16	Yoshitomi Pharmaceutical Corp.		1
	29.	91/07945	WO	A1	1991-06-13	LVMH Recherche	US5470579 cited herein appears to be an apparent English language equivalent	
	30.	94/03456	WO	A1	1994-02-17	Boehringer Ingelheim Int'l GmbH	US5719279 cited herein appears to be an apparent English language equivalent	
	31.	99/29695	WO	A1	6/17/1999	Astra Aktiebolag		
	32.	2002/14271	wo	A1	2002-02-21	Welfide Corporation	US7074794 cited herein appears to be an apparent English language equivalent	
	33.	2003/024965		A2		Novo Nordisk A/S		
	34.	2003/057200		A2		Novo Nordisk A/S		
	35.	2004/018467		A2	2004-03-04	Boehringer Ingelheim Pharma GmbH & Co. KG	CA2496325 cited herein appears to be an apparent English language equivalent	
	36.	2004/018468	wo	A2	2004-03-04	Boehringer Ingelheim Pharma GmbH & Co. KG	CA2496249 cited herein appears to be an apparent English language equivalent	
	37.	2004/028524		A1	2004-04-09	Eisai Co., Ltd.	US2006/0094722 cited herein appears to be an apparent English language equivalent	
—	38.	2004/033455		A2	1	Novo Nordisk		†

Examiner:	/Mark Berch/ (04/16/2008)	Date Considered:	
-----------	---------------------------	------------------	--

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Not for submission under 37 CFR 1.99) (Use several sheets if necessary)

Comparable to PTO/SB/08a (05-07)

_		
	Application Number:	10/716,141
	Filing Date:	November 18, 2003
	First Named Inventor:	Matthias ECKHARDT
	Art Unit:	1624
	Examiner Name:	Mark L. BERCH
	Attorney Docket Number:	01-1419

FOREIGN PATENT DOCUMENTS							
						CA2505389 cited herein appears to be	
					Boehringer Ingelheim	an apparent English language	
39.	2004/041820	WO	A1	2004-05-21	Pharma GmbH	equivalent	
					Boehringer Ingelheim	US2004/0138215 cited herein appears	
					Pharma GmbH & Co.	to be an apparent English language	
40.	2004/046148	wo	A1	2004-06-03		equivalent	
1 11					Sumitomo Pharm		
41.	2004/048379	WO	A1	2004-06-10			٧
					Boehringer Ingelheim	CA2508233 cited herein appears to be	
1 42					Pharma GmbH & Co.	an apparent English language	
42.	2004/050658	wo	A1	2005-06-17		equivalent	
12	0004/000000				Sumitom Pharm. Co.		11
43.	2004/096806	wo	A1	2004-11-11			7
1 44	00044400=00				Fujisawa Pharma		
44.	2004/108730	WO	A1	2004-12-16	Co., Ltd.		
						CA2529729 cited herein appears to be	
1.5	00044440=4					an apparent English language	
45.	2004/111051	WO	A1	2005-12-23	BI Int'l GmbH	equivalent	
						CA2543074 cited herein appears to be	
46.	0005/050004	1440		0005 00 00	D. I. III G. I. I.	an apparent English language	
40.	2005/058901	WO	A1	2005-06-30	BI Int'l GmbH	equivalent	
						CA2556064 cited herein appears to be	
47.	0005/00000	14/0		0005 00 00	Di la di Cashii	an apparent English language	
4/.	2005/082906	WO	A1	2005-09-09	BI Int'l GmbH	equivalent	
						CA2555050 cited herein appears to be	
48.	2005/085246	MO	A1	2005 00 15	BI Int'l GmbH	an apparent English language	
 70.	2003/003246	VVO	AI	2005-09-15	DI IIILI GIIIDA	equivalent	
					BI Pharma GmbH &	US2006079541 cited herein appears	
49.	2006/029769	WO	A1	2006-03-23		to be an apparent English language equivalent	
 	2000/029/09	V V O	- ^ '	2000-03-23	CO. NG	US2006142310 cited herein appears	
						to be an apparent English language	
50.	2006/048427	WO	A1	2006.05.11	BI Int'l GmbH	lo be an apparent English language equivalent	
50.	2000/040427	V V O	— A1	2000-05-11	Dainippon Sumitomo	CA2590912 cited herein appears to be	
51.	2006/068163	WO	A1	2006.06.20	Pharma Co., Ltd.	an English language equivalent	
71.	2000/000103	V V O		2000-00-29	F. Hoffmann-La	an English language equivalent	
52.	2007/017423	WO	A2	2007-02-15			
54.	2001/01/423	VVO	AZ	2007-02-15	Roche AG		

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initial*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages (s), volume-issue number(s), publisher, city and/or country where published.	$\sqrt{2}$	
	1.	AUGUSTYNS, K. et al., The Unique Properties of Dipeptidyl-peptidase IV (DPP IV/CD 26) and the Therapeutic Potential of DPP-IV Inhibitors, Current Medicinal Chemistry, Vol. 6, No. 4, 1999, pp. 311-327.		
	2.	BELJEAN-LEYMARIE et al., Hydrazines et hydrazones hétérocycliques. IV. Synthèses de dérivés de l'hydrazine dans la série des imidazo[4,5-d]pyridazinones-4, Can. J. Chem., Vol. 61, No. 11, 1983, pp. 2563-2566.	√	
	3.	BOLLAG, R.J. ET AL; "Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors," Endocrinology, Vol. 141, No. 3, 2000, pp. 1228-1235.		
	4.	BRITTAIN, H.G., "Methods for the Characterization of Polymorphs: X-Ray Powder Diffraction," Polymorphism in Pharmaceutical Solids, 1999, p. 235-238		

 $^{^{2}}$ $\sqrt{}$ indicates English Language translation is attached

Examiner: /Mark Berch/ (04/16/2008) Date Considered:

(Not for submission under 37 CFR 1.99) (Use several sheets if necessary)

Comparable to PTO/SB/08a (05-07)

Application Number:	10/716,141
Filing Date:	November 18, 2003
First Named Inventor:	Matthias ECKHARDT
Art Unit:	1624
Examiner Name:	Mark L. BERCH
Attorney Docket Number:	01-1419

5.	BUSSO ET AL., "Circulating CD26 is Negatively Associated with Inflammation in Human and Experimental Arthritis," Am. J. Path., Vol. 166, No. 2, Feb. 2005, pp. 433-442.	
	CAIRA, M.R., "Crystalline polymorphism of organic compounds" Topics in Current Chemistry, Springer, Berlin, Vol. 198,	
6.	1998, p. 163-208	
7.	CONARELLO, S.L. ET AL; "Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance," PNAS 2003; 100:6825-6830; originally published online May 14, 2003; information current as of December 2006. www.pnas.org/cgi/content/full/100/11/6825.	
8.	DEACON, C.F. ET AL; "Dipeptidyl peptidase IV inhabitation as an approach to the treatment and prevention of type 2 diabetes: a historical perspective;" Biochemical and Biophysical Research Communications (BBRC) 294 (2002) 1-4.	
	DeMEESTER, I. ET AL.; "CD26, let it cut or cut it down", Review: Immunology Today; August 1999, Vol. 20, No. 8	
	pp.367-375	
11.	POSPISILIK, ET AL; "Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β -Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats; Diabetes, Vol. 52, March 2003 pp 741-750.	
12.		
	SEDO, A. ET AL; "Dipeptidyl peptidase IV activity and/or structure homologs: Contributing factors in the pathogenesis of	
13.	rheumatoid arthritis?" Arthritis Research & Therapy 2005, Vol. 7, pp. 253-269	
15.	WOLFF, M.E.: "Burger's Medicinal Chemistry and Drug Discovery" Fifth Edition, Vol 1: Principles and Practice, pgs. 975-977, 1994, John Wiley & Sons, Inc.,	
16.	ZHONG, QING ET AL; "Glucose-dependent insulinotropic peptide stimulates proliferation and TGF-β release from MG-63 cells," Peptides 24 (2003) 611-616	
	Chemical Abstracts Accession No. 1987:95577: Abstract of ROMANENKO et al., "Synthesis and biological activity of 3-methyl, 7- or 8-alkyl, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," Farmatsevtichnii Zhurnal, 1986, (Kiev), Vol. 5, 1986, pp. 41-44.	
	Chemical Abstracts Accession No. 106:95577 ROMANENKO ET AL., "Synthesis and biological activity of 3-methyl, 7-or 8-alkyl-7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," Zaporozh. Med. Institute (1986)	
	YOSHIKAWA, SEIJI ET AL.: Chemical Abstract of Japanese Patent No. WO 2003/104229 "Preparation of purinone derivatives as dipeptidylpeptidase IV (DPP-IV) inhibitors 2003	
20.	International Search Report for PCT/EP03/09127 mailed November 28, 2003.	
21.	International Search Report for PCT/EP03/13648 mailed April 5, 2004.	
22.	International Search Report for PCT/EP2007/054270 mailed August 14, 2007.	
23.	International Search Report for PCT/EP2007/058181 mailed November 28, 2007.	
24.	International Search Report for PCT/EP2007/054204 mailed August 3, 2007.	
25.	International Search Report for PCT/EP2007/054201 mailed August 29, 2007	

Examiner:	/Mark Berch/ (04/16/2008)	Date Considered:
-----------	---------------------------	------------------

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.